ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.67
0.00%
US Tech 100
19,214.80
0.00%
S&P 500
5,477.90
0.16%
US Dollar vs CAD
1.36915
-0.10%
Bitcoin
60,766.06
-0.08%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. USOTC
  6. Silence Therapeutics PLC (PK) (SLNCF)

  7. Silence Therapeutics PLC (PK) (SLNCF) News

SLNCF

Silence Therapeutics (PK) (SLNCF)

Silence Therapeutics PLC (PK)
Date:
Sort by:
 Showing the most relevant articles for your search:USOTC:SLNCF
DateTimeSourceHeadlineSymbolCompany
06/20/20247:41AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]USOTC:SLNCFSilence Therapeutics PLC (PK)
05/07/20244:03PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersUSOTC:SLNCFSilence Therapeutics PLC (PK)
12/01/20236:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]USOTC:SLNCFSilence Therapeutics PLC (PK)
11/01/20236:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]USOTC:SLNCFSilence Therapeutics PLC (PK)
08/16/20236:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]USOTC:SLNCFSilence Therapeutics PLC (PK)
08/14/20234:01PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]USOTC:SLNCFSilence Therapeutics PLC (PK)
07/03/20236:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]USOTC:SLNCFSilence Therapeutics PLC (PK)
05/16/20233:02PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
05/01/20236:32AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
03/28/20237:01AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
02/08/20232:10PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)USOTC:SLNCFSilence Therapeutics PLC (PK)
01/12/20233:31PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
11/10/20227:31AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
10/20/20223:02PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)USOTC:SLNCFSilence Therapeutics PLC (PK)
09/29/20227:01AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
08/22/20223:14PMEdgar (US Regulatory)Statement of Ownership (sc 13g)USOTC:SLNCFSilence Therapeutics PLC (PK)
08/19/20223:31PMEdgar (US Regulatory)Statement of Ownership (sc 13g)USOTC:SLNCFSilence Therapeutics PLC (PK)
08/12/202212:32PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)USOTC:SLNCFSilence Therapeutics PLC (PK)
08/12/20225:11AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
08/11/20224:05PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
06/15/20223:33PMEdgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)USOTC:SLNCFSilence Therapeutics PLC (PK)
05/16/20227:34AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
05/16/20227:33AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
04/25/20227:31AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
04/04/20227:31AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
03/23/20227:30AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
03/17/202211:32AMEdgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)USOTC:SLNCFSilence Therapeutics PLC (PK)
02/22/20225:52AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
02/14/20224:23PMEdgar (US Regulatory)Statement of Ownership (sc 13g)USOTC:SLNCFSilence Therapeutics PLC (PK)
02/14/20224:12PMEdgar (US Regulatory)Statement of Ownership (sc 13g)USOTC:SLNCFSilence Therapeutics PLC (PK)
 Showing the most relevant articles for your search:USOTC:SLNCF

Your Recent History

TG
TRVC
Citigroup
TSXV
TTD
Tinkerine Studios
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved